Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X about a paper by Abdullah K. Malik et al. published in Nature Reviews:
“HCC remains a major challenge, ~900,000 cases per year with mortality nearly the same.
Curative options (resection, ablation and transplant) apply to only 10–20% of patients and recurrence reaches 70% at 5 yrs.
The field is moving toward biology-driven decision-making using biomarkers, PET, functional MRI, machine perfusion to increase transplant access and perioperative ICI to decrease recurrence.
SBRT is increasingly used for downstaging and bridging.”
Title: Improving surgical treatments for hepatocellular carcinoma
Authors: Abdullah K. Malik, Daniel Geh, Thomas R. Jeffry Evans, Pierce K. H. Chow, Derek A. Mann, Steven A. White
You can read the full article in Nature Reviews – Gastroenterology and Hepatology.
More posts featuring Oscar Tahuahua.